Press Releases

BIOMS MEDICAL ANNOUNCES PROFESSOR HANS-PETER HARTUNG AS NATIONAL COORDINATOR IN GERMANY FOR PIVOTAL MULTIPLE SCLEROSIS TRIAL

Edmonton, Alberta, November 16, 2006 – BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), is pleased to announce Professor Hans-Peter Hartung as National Coordinator in Germany for the ongoing pivotal phase II/III trial of its lead drug, MBP8298, a proprietary synthetic peptide for the treatment of multiple sclerosis. Professor Hartung is also a member of the Clinical Advisory Group for the international phase II/III trial.

Professor Hartung is Professor and Chairman, Department of Neurology at Heinrich-Heine-Universität Düsseldorf in Germany.

“Professor Hartung is world renowned in the area of multiple sclerosis and we are very pleased to have his support and involvement in our international pivotal phase III trial for MBP8298,” said Kevin Giese, President and CEO of BioMS Medical.

Professor Hartung serves on a number of executive boards, including ECTRIMS as President, the European Charcot Foundation, the International Society of Neuroimmunology, WHO Working Group on Multiple Sclerosis, GBS Foundation International, the Medical Advisory Board of the International (MSIF) and the German MS Society. He is also member of the Editorial Board of a number of international journals. Professor Hartung is a Corresponding Fellow of the American Academy of Neurology and American Heart Association and Corresponding Member of the American Neurological Association. Professor Hartung has authored or co-authored more than 400 articles in peer-reviewed journals, contributed more than 80 book chapters and edited seven books.

Pivotal Phase II/III Multiple Sclerosis Trial

BioMS Medical is currently enrolling patients across Canada and Europe in its pivotal Phase II/III clinical trial evaluating MBP8298 for the treatment of secondary progressive multiple sclerosis (SPMS). The trial is a randomized, double-blind study enrolling approximately 553 patients who will be administered either MBP8298 or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes. Time to disease progression in patients with other HLA-DR types will be assessed separately as an exploratory arm of the same study. To date the trial has successfully passed five safety reviews by its independent Data Safety Monitoring Board.

This press release may contain forward-looking statements, which reflect the Corporation’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide (MBP8298) will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.